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Summary: Intact arterial vessel wall is not thrombogenic. Disorders of the endothelium in connection with patho-
logical conditions such as atherosclerosis, hyperlipidaemia, hypertension and hyperuricemia induce interaction of
surfaces of high thromboplastic activity with the blood stream. In such situations local formation of thrombin will
take place immediately. Evidence is presented for the essential and unique activation of the extrinsic pathway of the
plasmatic coagulation system. The local formation of thrombin at pathologically altered arterial wall seems to be an
important trigger for arterial thrombosis and haemostasis. It could be that in vivo the initial step of thrombogenesis
depends upon the formation of the activator complex between tissue-thromboplastin and factor VII.
Thromboplastin-Aktivität in humanen arteriellen Gefäßwänden und ihre Wirkung auf das plasmatische Gerinnungs-
system
Zusammenfassung: Die intakte arterielle Gefäßwand ist nicht thrombogen. Bei Endothel-Schädigungen, ausgelöst
durch pathologische Bedingungen wie Atherosklerose, Hyperlipidämie, Hypertonie und Hyperurikämie, erscheint
ThromboplastinrAktivität an der Oberfläche und reagiert mit dem Blutstrom. Unter solchen Umständen tritt dort
sofort lokalisierte Thrombinbildung ein. Resultate der eigenen experimentellen Untersuchungen bestätigen die
Aktivierung des plasmatischen Gerinnungssystems über den extrinsischen Reaktionsablauf. Dabei kommt der loka-
lisierten Thrombinbildung an pathologisch veränderten Gefäßen eine Bedeutung in der arteriellen Thrombose- und
Hämostase-Auslösung zu. Für die Thrombogenese muß die Bildung des Aktivator-Komplexes zwischen Thrombo-
plastin und Faktor VII als Initial-Reaktion angesehen werden.
Introduction
The subendptheliäl tissue and the endothelial cells
themselves contain high thromboplastic activity (1).
Tissue-thromboplastin fixed in the nricrosomal bio-
membrane is the specific physiological activator of
the extrinsic blood clotting pathway. Under patiu>
logical conditions the thromboplastic activity comes
into contact with the blood. A highly specific and rapid
activation of factor VII followed by thrombin formation
at the disordered vessel wall position can be assumed.
The high affinity of thrombin to thrombocytes and
fibrinogen under physiological conditions may initiate
systemic thrombin formation with eventual conse-
quences such as mypcardial infarction, cerebral stroke,
pulmonary embolism (2).
Our studies are designed to elucidate the initial reaction,
i.e. formation of a complex between wall-localized throm-
boplastin and factor VII. It is likely that this step is at the




Aortic material (aorta abdominalis) was kindly supplied by
Prof. L. Bianchi, Pathological Institute of the University of
Basel. Surgical specimens of arterial vessel segments were
kindly provided by Dr. B. Nachbur, Surgical Department, Insei-
spitäl Bern. Vessel segments were kept in Tris-buffered saline
pH 7.4 at 4 °C. The connective tissue at the outside was care-
fully removed and the buffer-solution changed several times to
remove most of blood contaminants.
For the experiments the vessels were cut off alongside and
divided in square parts of 1 cm2. With respect to the degree
of alteration of the arterial wall, the segments were tenta-
tively classified into those with atherosclerotic plaques.
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severe atherosclerotic ulceration, wall thickening with ent-
rapped hydroxyapatite and/or cholesterol parts.
Near normal arterial wall specimens were also obtained for
our investigations from patients undergoing surgery.
Plasma
Normal human titrated plasma was prepared from blood
collected at the Swiss Red Cross Blood Bank, Kantons-
spital Basel, 9 vol. to 1 vol. of 0.1 mol/1 sodium citrate
solution. The blood samples were centrifuged immediately
at 1500 £ for 20 minutes. Plasma specimens from 20 donors
were pooled and shock-frozen in aliquots of 2.0 ml.
Factor VH-deficient plasma was obtained from GEORGE
KING Bio-Medical Corp., USA. The frozen plasma repre-
sented a congenital, factor VII-deficient human plasma from a
single donor with a factor VII activity < 1% of normal according
to the declaration.
Diagnostic reagents like Ca thromboplastin and partial thrombo-
plastin time reagent were manufactured by Diagnostica
ROCHE, Basel. Solutions of 0.025 mol/1 calcium chloride,
0.2 mol/1 trisodium citrate and saline were prepared with
commercial substances of p.a. grade.
normal plasma with pathologically altered specimens
of vessel-wall does not give effects detectable with pro-
thrombin time. The prothrombin time values seem to
be influenced by the action of citrate in human citrated
plasma. Its strong calcium chelation effect inhibits the
formation of the complex between factor VII and the
thromboplastic activity localized on wall damage. To
study this effect the plasma recalcifieation time was
determined in the absence or presence of vessel seg-
ments. Results are given in the next experimental part.
The increase of partial thromboplastin time in the
measurement with factor VII-deficient plasma could
be induced by adsorption of factor XII onto damaged
vessel surface. No increase of partial thromboplastin
time is detectable by incubation of plasma with normal
non^disordered vessels, i.e. vessel from surgery patient
(accident leg amputation).
Clotting time measurement
All clotting time measurements except recalcification time,
were determined by use of the BBL·Fib omete .
Recalcification time was determined as follows: 1.0 ml of
plasma without or with added vessel segment was incubated
for 3 minutes at 37 °C. Then 1.0 ml of 0.025 mol/1 calcium
chloride solution prewarmed to 37 °C was added at once and
coagulation time measured by the manual tilt-tube technique
in a 37 °C water bath.
For prothrombin time determination 0.2 ml prewarmed (37 °C)
Ca thromboplastin ROCHE solution was added to 0.1 ml plasma,
preincubated or not with a vessel-segment. The clotting time was
measured with the BBL-Fibrometer.
For partial thromboplastin time estimation, 0.1 ml plasma (as
used for prothrombin time determination) and 0.1 ml partial
thromboplastin time reagent ROCHE were mixed and pre-
incubated at 37 °C for 3 minutes. Then 0.1 ml prewarmed
(37 °C) 0.025 mol/1 calcium chloride solution was added and
the clotting time determined with the BBL-Fibrometer.
Results
Alterations of prothrombin time and partial thrombo-
plastin time of normal and factor VH-deficient plasma,
preincubated with vessel segment
Arterial wall segments (from aorta abdominalis) with a
surface area of 1 cm2 were added to 2.0 ml of normal
citrated human plasma or to factor VII-deficient human
plasma. After 15 minutes with occasional agitation at
room temperature the plasmas were harvested with a
pipette and tested immediately by prothrombin time
and partial thromboplastin time measurements. Results
are summarized in table 1.
Slight increases of prothrombin time from 14.5 to 15.7
seconds for normal plasma and from 22.3 to 23.4
seconds for factor VII-deficient plasma were observed.
No difference was noticed between vessel material
from dissection and from surgery. Preincubation of
Influence of vessel segments added to plasma upon
recalcification time
Table 2 contains the values obtained with normal and"
factor VII-deficient plasma. As can be seen, recalcifica-
tion time values were markedly decreased, especially in
normal human plasma, whereas in factor VII-deficient
plasma, recalcification time reduction was less pro-
nounced. In these experiments, citrate action on Ca-
complexation was eliminated and the formation of an
activator complex between thromboplastin and factor
VII and other Ca-dependent reaction steps was not
inhibited.
Recalcification time values of fresh normal human
citrated plasma incubated with the same vessel segment
after several preincubations in normal plasma
A denuded aorta segment (surface area 1 cm2) was
placed into 1.0 ml of normal human plasma and pre-
warmed for 2 minutes at 37 °C. Recalcification time
was then estimated by adding 1.0 ml solution of 0.025
mol/1 CaCl2. At the end of clotting the segment was
removed, freed from any adhering fibrin clot, washed
with saline and recalcification time estimations repeated
with this segment and fresh plasma. After this second
determination, the procedure of fibrin elimination was
repeated. The segment was either washed with saline or
with a solution of 0.2 mol/1 sodium citrate. Before-
adding the segments to fresh plasma, normal and factor
VH-deficient, contaminating solution was removed with
filter paper.
Figure 1 summarizes the results of these experiments.
After the first recalcification time estimation in the
presence of the vessel segment, the values decreased;
the second preincubation was followed by a further
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Tab. 1. Alterations of prothrombin time and partial thromboplastin time values of normal and factor VII-deficient plasma after pre-
incubation with "normal" and disordered vessel (aorta abdominalis) segments.
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Normal plasma Factor VII-
deficient
plasma
Partial thromboplastin time (s)
Normal plasma Factor VII-
deficient
plasma
MN 46 Accident leg amputation 14.5 30.3
PW 73 Atherosclerotic plaques ulc. 15.1 30.7
TS 53 Atherosclerotic plaques 15.3 22.5
Β 63 Atherosclerosis 15.1 19.8
Average from 4 samples
Standard deviation
Values without wall contact
15.0 25.8
± 0.3 ± 5.5
14.5 22.3
± 1.0 ± 2.0












Average from 11/4 samples
Standard deviation
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Fig. 1. Recalcification time decreased by segment from earlier
recalcification time estimation after repeated washing.
Hatched plots represent values from normal plasma, white
plots represent values from factor VII-deficient plasma
(indicated standard deviations represent 4 experiments).
B: recalcification time in the presence of segment.
A: recalcification time without segment.
B: recalcification time in the presence of segment.
Cj: recalcification time repeated with normal plasma and
saline-washed segment from B.
Q: recalcification time with factor VII-deficient plasma
and segment after recalcification time estimation
with normal plasma and saline-washed segment.
Dj: recalcification time with normal plasma and saline-
washed segment from GI .
D2: recalcification time with factor VII-deficient plasma
and segment after 2fold recalcification time estima-
tion with normal plasma and saline-washed segment.
E: recalcification time with segments from DI and 2
after washing with sodium citrate solution, 0.2 mol/1.
decrease. Thereafter no further decrease could be
observed. These effects might be explained by satura-
tion of the thromboplastin molecules of the vessel
wall with factor VII from the previous contact with
normal plasma, leading to optimal complex formation
between tissue thromboplastin and factor VEL Vessel
segments preincubated in normal plasma also decreased,
to a similar extent, the recalcification time value of
factor VII-deficient plasma, since the segment contains
the active complex of thromboplastin factor Vila.
When the preincubated segment was washed with 0.2
mol/1 sodium citrate solution, an increase of recalcifica-
tion time values was found on repeated estimation. We
assume that citrate removes factor VII a from tissue
thromboplastin, i.e. destroys the activator cpmplex
through Ca-chelation by citrate.
An approach to determine the thromboplastic activity
of the different wall structures
Wall sections were prepared from a fresh aorta, which
was carefully freed from any connective tissue and
Recalcification time estimation
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washed free of blood contaminants with saline. The
structures removed, beginning from the inside of the
vessel wall, were identified by use of a microscope
and a dying-technique using Evans Blue. We assume
that the first layer mostly contains disrupted endo-
thelial cells and the basal laminar membrane. The
underlying layers represent structures from the ultima,
media and the adventitia.
Table 3 gives the results of thromboplastic activity
found in the various wall structures. Our preparations
represented very crude fractions of structures and the
estimated values are only approximations. It appears
that structures going from inside to outside of the
vessel wall contain decreasing amounts of thrombo-
plastic activity. These observations are not new and are
herewith confirmed. For induction of thrombogenesis
the content of thromboplastic activity in the endo-
thelial and subendothelial layers represents an essential
prerequisite.
Discussion
For the elucidation of thrombogenesis, experiments
were carried out using exclusively human arterial tissue
and human plasma. The real mechanism of the early
phase of thrombogenesis remains still obscure. From
own results we assume that the initial reaction after
vessel wall damage may be the formation of a complex
between thromboplastin localized in the wall and
plasma clotting factor VII. Tissue segments of patients
do no affect recalcification time of factor VII-deficient
plasma appreciably, unless such tissue segments have
previously been in contact with normal plasma, thus
binding factor VII for subsequent reaction with thrombo-
plastin in the tissue (see experiments in figure 1). An
activation of factor XII through contact with altered
wall segments does not seem to take place, because no
. change could be observed in the recalcification time of
factor VII-deficient plasma without or with wall seg-
ment. Thus it may be concluded that factor VII is
essential for normal hemostatic function and induces
J. Clin. Chem. Gin. Biochem. / Vol. 18, 1980 / No. 9
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a rapid formation of thrombin upon contact with patho-
logically available thromboplastin. Thrombin itself may
be the trigger for known subsequent reactions, i.e.
adhesion and aggregation of thrombocytes and fibrin
clot formation. Patients with very low factor VII
activity (< 1%) produce severe clotting defects with
hemorrhagies into cerebral and mucosal tissues (3,4).
The defect of the clotting mechanism in such patients is
not corrected by factor XII activation or other "shunts"
forhemostasis.M^erus et al. (5) have found that throm-
bin must be formed very early in the course of thrombo-
genesis. But in the case of severe congenital factor XII
deficiency no hemostatic complications have been
found. This fact diminishes the role of collagenic
structures as the main physiological trigger in thrombo-
genesis. Thus thrombin formed via the extrinsic pathway
at an early stage induces fibrin formation, platelet ad-
hesion/aggregation and accelerates the activation of the
plasmatic coagulation system. Thrombin furthermore is
a potent mitogenic substance which may fulfil an impor-
tant function in wall repair (6).
Acknowledgements
We thank Dr. B. Nachbur, Surgical Department, Inselspital Bern,
and Prof. L. Bianchi, Pathological Institute, University Basel,
for gifts of arterial tissues.
References
1. Freytag, J. W., Dalymple, P. N., Maguire, M. H., Strickland,
D. K., Carraway, K. L. & Hudson, B. G. (1978), J. Biol.
Chem. 253, 9069-9074.
2. Lüscher, E. F. (1978), Agents + Actions 8, 282-290.
3. Grosse, K. P., Neidhardt, B., Seiler, G., Schricker, K. Th.
& Dorn, G. (1974), Klin. Pädiat. 168, 29-33.
4. Zimmermann, R., Ehlers, G., Ehlers, W., von Voss, H.,
Göbel, U. & Wahn, U. (1979), Blut 38, 119-125.
5. Majerus, P. W. & Miletich, J. P. (1978), Ann. Rev. Med.
29,41-49.




F. Hoffmann-La Roche & Co. AG
CH-4002 Basel
J. Clin. Chem. din. Biochem. / Vol. 18,1980 / Np. 9

